| Non-Small Cell Lung Carcinoma

Alunbrig vs Tagrisso

Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.

Deep comparison between: Alunbrig vs Tagrisso with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTagrisso has a higher rate of injection site reactions vs Alunbrig based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tagrisso but not Alunbrig, including UnitedHealthcare

Category

Alunbrig

Tagrisso

At A Glance

RouteOral

FrequencyOnce daily

ClassALK inhibitor

RouteOral

FrequencyDaily

ClassEGFR kinase inhibitor

Indications

Non-Small Cell Lung Carcinoma

Non-Small Cell Lung Carcinoma

Dosing

Non-Small Cell Lung Carcinoma 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily; may be taken with or without food.

Adjuvant Non-Small Cell Lung Carcinoma 80 mg orally once daily until disease recurrence, unacceptable toxicity, or for up to 3 years.

Locally advanced, unresectable (Stage III) Non-Small Cell Lung Carcinoma Following platinum-based chemoradiation therapy, 80 mg orally once daily until disease progression or unacceptable toxicity.

First-line metastatic Non-Small Cell Lung Carcinoma (monotherapy) 80 mg orally once daily until disease progression or unacceptable toxicity.

First-line locally advanced or metastatic Non-Small Cell Lung Carcinoma (combination) 80 mg orally once daily in combination with pemetrexed and platinum-based chemotherapy until disease progression or unacceptable toxicity.

Previously treated EGFR T790M mutation-positive metastatic Non-Small Cell Lung Carcinoma 80 mg orally once daily until disease progression or unacceptable toxicity.

Contraindications

—

Drug Interactions

1063View drug interactions

1081View drug interactions

Adverse Reactions

Most common (>=10%) diarrhea, nausea, rash, cough, hypertension, fatigue, myalgia, headache, dyspnea, back pain, pruritus, edema, pyrexia, dizziness, pneumonia, arthralgia, constipation, bradycardia, abdominal pain, upper respiratory tract infection, peripheral neuropathy, stomatitis, vomiting, increased blood cholesterol

Serious ILD/pneumonitis, hypertension, bradycardia, visual disturbance, CPK elevation, pancreatic enzyme elevation, hepatotoxicity, hyperglycemia, photosensitivity

Most common (>=20%) Diarrhea, rash, musculoskeletal pain, nail toxicity, dry skin, stomatitis, fatigue.

Serious ILD/pneumonitis, QTc interval prolongation, cardiomyopathy, keratitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, cutaneous vasculitis, aplastic anemia.

Postmarketing Erythema multiforme major, Stevens-Johnson syndrome, toxic epidermal necrolysis, cutaneous vasculitis, erythema dyschromicum perstans, aplastic anemia.

Pharmacology

Brigatinib is a tyrosine kinase inhibitor (TKI) with activity against ALK, ROS1, IGF-1R, FLT-3, and EGFR deletion and point mutations, inhibiting ALK autophosphorylation and downstream signaling proteins (STAT3, AKT, ERK1/2, S6) in ALK-positive NSCLC cell lines and xenograft models.

Osimertinib is a kinase inhibitor that irreversibly binds to mutant EGFR forms (T790M, L858R, and exon 19 deletions) at approximately 9-fold lower concentrations than wild-type EGFR, inhibiting tumor cell proliferation in EGFR mutation-positive NSCLC; it also inhibits HER2, HER3, HER4, ACK1, and BLK at clinically relevant concentrations.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Alunbrig